Turning To Not-For-Profits, AstraZeneca Bolsters Early Stage R&D

With patent expirations of major drugs looming, pharmaceutical companies are looking to trim expenses, especially in R&D, where expansive budgets have not generated returns – at least in terms of marketable products.